Pharmafile Logo
Pharmafocus logo
Advanced Search

rova-t

Showing 6 posts of 6 posts found.

abbvie_0

AbbVie shuts down Rova-T development in first-line advanced small-cell lung cancer following another trial failure

August 30, 2019
Medical Communications, Research and Development AbbVie, pharma, rova-t, small-cell lung cancer

AbbVie has announced its intention to terminate development of Rova-T (rovalpituzumab tesirine) in the first-line maintenance of advanced small-cell lung …

News
abbvie_0

AbbVie records an estimated $4billion in impairment charges after failure of cancer drug Rova-T

January 8, 2019
Manufacturing and Production AbbVie, M&A, MA, Stemcentrx, acquisition, rova-t

US firm AbbVie has said that it will record an estimated $4 billion in impairment charges related to the abandonment …

News
lab

AbbVie and BMS partner for Rova-T, Opdivo, Yervoy cancer combo

July 26, 2016
Manufacturing and Production, Research and Development AbbVie, BMS, Yervoy, opdivo, rova-t

AbbVie and Bristol-Myers Squibb have announced that they will collaborate on a clinical trial to test some of their leading …

News
abbvie_0

AbbVie says Stemcentrx’ lung cancer drug shows some benefits in early trials

June 6, 2016
Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AbbVie, Stemcentrx, drug trial, lung cancer, rova-t

US drug firm AbbVie (NYSE: ABBV) said its early-stage trials for its drug to treat an aggressive form of lung …

News
abbvie_0

AbbVie says Stemcentrx’ stem cell drug shows some benefits in early trials

June 6, 2016
Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AbbVie, Stemcentrx, drug trial, lung cancer, rova-t

US drug firm AbbVie (NYSE: ABBV) said its early-stage trials for its drug to treat an aggressive form of lung …

News
abbvie_0

AbbVie expands oncology portfolio with $5.8 billion Stemcentrx acquisition

April 29, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, acquisition, rova-t, stremcentrx, takeover

AbbVie (NYSE: ABBV) has announced the acquisition of Stemcentrx, and its lead late stage, lung cancer candidate Rova-T (rovalpituzumab tesirine), …

News

Latest content

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024

Intra-Cellular Therapies shares phase 3 results for major depressive disorder therapy

April 17, 2024

Novartis shares new data about Fabhalta for IgAN treatment

April 16, 2024